Last reviewed 2026-04-20 · How we verify

Lucimicina (LUCIMYCIN)

Phase 2 active Small molecule

Lucimicina (generic name: LUCIMYCIN) is a lucimycin drug. It is currently in Phase 2 development.

Lucimicina works by binding to a specific target, but its target is currently unknown.

Lucimicina (LUCIMYCIN) is a small molecule drug in the lucimycin class, but its target and mechanism of action are unknown. Its commercial status and approved indications are also unclear. As a result, key safety considerations and pharmacokinetic properties such as half-life and bioavailability are not well established. Further research is needed to fully understand this drug. Its ownership and patent status are also unknown.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	LUCIMYCIN
Drug class	lucimycin
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells are like locks, and Lucimicina is a key that fits into one of those locks. When it binds, it can either turn the lock on or off, depending on the type of lock and the key's shape. This can help control the activity of certain cellular processes.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Lucimicina CI brief — competitive landscape report
Lucimicina updates RSS · CI watch RSS

Frequently asked questions about Lucimicina

What is Lucimicina?

Lucimicina (LUCIMYCIN) is a lucimycin drug.

How does Lucimicina work?

Lucimicina works by binding to a specific target, but its target is currently unknown.

What is the generic name of Lucimicina?

LUCIMYCIN is the generic (nonproprietary) name of Lucimicina.

What drug class is Lucimicina in?

Lucimicina belongs to the lucimycin class. See all lucimycin drugs at /class/lucimycin.

What development phase is Lucimicina in?

Lucimicina is in Phase 2.

Drug class: All lucimycin drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing